Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 1
2009 1
2012 1
2014 5
2015 2
2016 1
2017 2
2018 1
2019 1
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Waldenström macroglobulinemia.
Ghobrial IM, Witzig TE. Ghobrial IM, et al. Curr Treat Options Oncol. 2004 Jun;5(3):239-47. doi: 10.1007/s11864-004-0015-5. Curr Treat Options Oncol. 2004. PMID: 15115652 Free PMC article. Review.
The disease is uncommon and there is a lack of clear diagnostic criteria. WM is treatable but not curable and long-term survival is possible. Therefore, the treating physician needs to carefully balance the risks and benefits of treatment. ...
The disease is uncommon and there is a lack of clear diagnostic criteria. WM is treatable but not curable and long-term survival is p …
Long-term outcomes among adults with Langerhans cell histiocytosis.
Goyal G, Acosta-Medina AA, Abeykoon JP, Dai C, Ravindran A, Vassallo R, Ryu JH, Shah MV, Bennani NN, Young JR, Bach CR, Ruan GJ, Zanwar S, Tobin WO, Koster MJ, Davidge-Pitts CJ, Gruber LM, Dasari S, Rech KL, Go RS. Goyal G, et al. Blood Adv. 2023 Nov 14;7(21):6568-6578. doi: 10.1182/bloodadvances.2023010706. Blood Adv. 2023. PMID: 37698994 Free PMC article.
Advances in the treatment of Langerhans cell histiocytosis (LCH) have resulted in a growing survivor population. There is a lack of data on long-term outcomes among adults with LCH. We conducted a retrospective record review of 219 adults (aged 18 years) with LCH. ...
Advances in the treatment of Langerhans cell histiocytosis (LCH) have resulted in a growing survivor population. There is a lack of data on …
Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists.
Bacon CM, Du MQ, Dogan A. Bacon CM, et al. J Clin Pathol. 2007 Apr;60(4):361-72. doi: 10.1136/jcp.2005.031146. Epub 2006 Sep 1. J Clin Pathol. 2007. PMID: 16950858 Free PMC article. Review.
Although MALT lymphomas are clinically indolent, the disease is typically chronic, requiring long-term clinical surveillance and, often, repeated biopsies. Pathologists thus play a central role in the diagnosis and management of these patients. ...
Although MALT lymphomas are clinically indolent, the disease is typically chronic, requiring long-term clinical surveillance and, oft …
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.
Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gormley N, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Kwong YL, Little RF, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Nair A, Nastoupil L, Robertson K, Sidana S, Smedby KE, Sonneveld P, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Seymour JF, Habermann TM. Thanarajasingam G, et al. Lancet Haematol. 2022 May;9(5):e374-e384. doi: 10.1016/S2352-3026(22)00045-X. Lancet Haematol. 2022. PMID: 35483398 Free PMC article. Review.
In 2018, a Commission comprising patient advocates, clinicians, clinical investigators, regulators, biostatisticians, and pharmacists representing a broad range of academic and clinical cancer expertise examined issues of adverse event evaluation in the context of both newer and …
In 2018, a Commission comprising patient advocates, clinicians, clinical investigators, regulators, biostatisticians, and pharmacists repres …
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity.
Wang Z, Yin C, Lum LG, Simons A, Weiner GJ. Wang Z, et al. J Hematol Oncol. 2021 Dec 9;14(1):204. doi: 10.1186/s13045-021-01216-w. J Hematol Oncol. 2021. PMID: 34886888 Free PMC article.
Previous work in our laboratory has shown that T cell help in the form of interleukin-2 maintains long-term NK cell viability and NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). ...Brief (4 h to 2 day) bsAb exposure was sufficient to enhance long-term …
Previous work in our laboratory has shown that T cell help in the form of interleukin-2 maintains long-term NK cell viability and NK …
Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis.
Strouse CS, Larson MC, Ehlers SL, Yost KJ, Maurer MJ, Ansell SM, Inwards DJ, Johnston PB, Micallef IN, Link BK, Farooq U, Cerhan JR, Thompson CA. Strouse CS, et al. JCO Oncol Pract. 2022 Jul;18(7):e1069-e1080. doi: 10.1200/OP.21.00694. Epub 2022 May 20. JCO Oncol Pract. 2022. PMID: 35594505 Free PMC article.
PURPOSE: This study assessed the long-term quality of life (QOL) of patients with aggressive lymphoma subtypes treated with autologous hematopoietic cell transplant (autoHCT) compared with those without history of transplant. ...
PURPOSE: This study assessed the long-term quality of life (QOL) of patients with aggressive lymphoma subtypes treated with autologou …
Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study.
Habermann TM, Thompson CA, LaPlant BR, Bauer BA, Janney CA, Clark MM, Rummans TA, Maurer MJ, Sloan JA, Geyer SM, Cerhan JR. Habermann TM, et al. Am J Hematol. 2009 Dec;84(12):795-8. doi: 10.1002/ajh.21554. Am J Hematol. 2009. PMID: 19894247 Free PMC article.
No published survey has specifically addressed the beliefs, knowledge, and usage of complementary and alternative medicine (CAM) in long-term (5-20 years) lymphoma survivors alone. In this pilot project, 95 subjects were randomly selected from a population of 2,475 long- …
No published survey has specifically addressed the beliefs, knowledge, and usage of complementary and alternative medicine (CAM) in long- …
Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.
Luchtel RA, Dasari S, Oishi N, Pedersen MB, Hu G, Rech KL, Ketterling RP, Sidhu J, Wang X, Katoh R, Dogan A, Kip NS, Cunningham JM, Sun Z, Baheti S, Porcher JC, Said JW, Jiang L, Hamilton-Dutoit SJ, Møller MB, Nørgaard P, Bennani NN, Chng WJ, Huang G, Link BK, Facchetti F, Cerhan JR, d'Amore F, Ansell SM, Feldman AL. Luchtel RA, et al. Blood. 2018 Sep 27;132(13):1386-1398. doi: 10.1182/blood-2018-03-838524. Epub 2018 Aug 9. Blood. 2018. PMID: 30093402 Free PMC article.
About 30% of ALK-negative ALCLs have rearrangements of DUSP22 and have excellent long-term outcomes with standard therapy. To better understand this group of tumors, we evaluated their molecular signature using gene expression profiling. ...
About 30% of ALK-negative ALCLs have rearrangements of DUSP22 and have excellent long-term outcomes with standard therapy. To better …
Second malignancies in patients with primary central nervous system lymphoma.
Wang J, Pulido JS, O'Neill BP, Johnston PB. Wang J, et al. Neuro Oncol. 2015 Jan;17(1):129-35. doi: 10.1093/neuonc/nou105. Epub 2014 Jun 19. Neuro Oncol. 2015. PMID: 24948826 Free PMC article.
Therefore, screening for SMs should also be considered in long-term follow-up of patients with PCNSL. In addition, the high incidence of subsequent cancer, synchronous cancer, and frequently seen nonmelanoma skin cancers may all indicate an immunosuppressed state in patien …
Therefore, screening for SMs should also be considered in long-term follow-up of patients with PCNSL. In addition, the high incidence …
Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution.
Kenderian SS, Habermann TM, Macon WR, Ristow KM, Ansell SM, Colgan JP, Johnston PB, Inwards DJ, Markovic SN, Micallef IN, Thompson CA, Porrata LF, Martenson JA, Witzig TE, Nowakowski GS. Kenderian SS, et al. Blood. 2016 Apr 21;127(16):1960-6. doi: 10.1182/blood-2015-08-665505. Epub 2016 Feb 2. Blood. 2016. PMID: 26837698 Free PMC article.
A number of reports have shown a propensity of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) to transform into diffuse large B-cell lymphoma (DLBCL). Long-term data on the incidence and outcomes of transformed NLPHL are lacking. ...The 5-year overall survival (OS …
A number of reports have shown a propensity of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) to transform into diffuse large B-cel …
19 results